Skip to main content

Advertisement

SpringerLink
Log in

MEF2D/Wnt/β-catenin pathway regulates the proliferation of gastric cancer cells and is regulated by microRNA-19

  • Original Article
  • Published:
Tumor Biology

Abstract

The underlying molecular pathogenesis in gastric cancer remains poorly unknown. The transcription factor myocyte enhancer factor 2D (MEF2D) participates in the initiation and development of many human cancers. However, its potential roles in gastric cancer have surprisingly not been studied. In present study, we first explored MEF2’s expression in gastric cancer, finding that only MEF2D rather than MEF2A, 2B, or 2C was elevated in gastric cancer clinical specimens. Furthermore, immunohistochemical analysis on the tissue samples obtained from 260 patients with gastric cancer revealed that MEF2D expression was significantly associated with the clinical stage, vascular invasion, metastasis, and tumor size. Gastric cancer patients with MEF2D expression showed a significantly shorter overall survival time compared with that of patients lacking of MEF2D. Multivariate analysis revealed that MEF2D expression was an independent prognostic factor for overall survival. These results indicated that MEF2D was a prognostic marker for gastric cancer. Notably, MEF2D silencing was able to reduce the proliferation and survival of gastric cancer cells. Further study revealed that MEF2D suppression significantly inactivated the oncogenic Wnt/β-catenin pathway. Downregulation of MEF2D inhibited the tumorigenesis of gastric cancer cells in nude mice. Finally, MEF2D is a direct target of miR-19, which was found to be decreased in gastric cancer clinical specimens. Collectively, we found that miR-19/MEF2D/Wnt/β-catenin regulatory network contributes to the growth of gastric cancer, hinting a new promising target for gastric cancer treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Shah MA, Kelsen DP. Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compr Cancer Netw. 2010;8:437–47.

    CAS  Google Scholar 

  2. Compare D, Rocco A, Nardone G. Risk factors in gastric cancer. Eur Rev Med Pharmacol Sci. 2010;14:302–8.

    CAS  PubMed  Google Scholar 

  3. Lynch HT, Grady W, Suriano G, Huntsman D. Gastric cancer: new genetic developments. J Surg Oncol. 2005;90:114–33.

    Article  CAS  PubMed  Google Scholar 

  4. Aung P, Oue N, Mitani Y, Nakayama H, Yoshida K, Noguchi T, et al. Systematic search for gastric cancer-specific genes based on sage data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer. Oncogene. 2006;25:2546–57.

    Article  CAS  PubMed  Google Scholar 

  5. Sun W, Wu Y, Yu X, Liu Y, Song H, Xia T, et al. Decreased expression of long noncoding rna ac096655. 1–002 in gastric cancer and its clinical significance. Tumor Biol. 2013;34:2697–701.

    Article  CAS  Google Scholar 

  6. Sakakura C, Hagiwara A, Miyagawa K, Nakashima S, Yoshikawa T, Kin S, et al. Frequent downregulation of the runt domain transcription factors runx1, runx3 and their cofactor cbfb in gastric cancer. Int J Cancer. 2005;113:221–8.

    Article  CAS  PubMed  Google Scholar 

  7. Li Q, Zhang N, Jia Z, Le X, Dai B, Wei D, et al. Critical role and regulation of transcription factor foxm1 in human gastric cancer angiogenesis and progression. Cancer Res. 2009;69:3501–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Li T, Lu Y, Zhao X, Guo H, Liu C, Li H, et al. Microrna-296-5p increases proliferation in gastric cancer through repression of caudal-related homeobox 1. Oncogene. 2014;33:783–93.

    Article  PubMed  Google Scholar 

  9. Wang B, Cai Z, Lu F, Li C, Zhu X, Su L, et al. Destabilization of survival factor mef2d mRNA by neurotoxin in models of Parkinson’s disease. J Neurochem. 2014;130:720–8.

    Article  CAS  PubMed  Google Scholar 

  10. Black BL, Olson EN. Transcriptional control of muscle development by myocyte enhancer factor-2 (mef2) proteins. Annu Rev Cell Dev Bi. 1998;14:167–96.

    Article  CAS  Google Scholar 

  11. Bai X, Wu L, Liang T, Liu Z, Li J, Li D, et al. Overexpression of myocyte enhancer factor 2 and histone hyperacetylation in hepatocellular carcinoma. J Cancer Res Clin. 2008;134:83–91.

    Article  CAS  Google Scholar 

  12. Bai X, Zhang Q, Ye L, Liang F, Sun X, Chen Y, et al. Myocyte enhancer factor 2c regulation of hepatocellular carcinoma via vascular endothelial growth factor and wnt/β-catenin signaling. Oncogene. 2014.

  13. Ma L, Liu J, Liu L, Duan G, Wang Q, Xu Y, et al. Overexpression of the transcription factor mef2d in hepatocellular carcinoma sustains malignant character by suppressing g2–m transition genes. Cancer Res. 2014;74:1452–62.

    Article  CAS  PubMed  Google Scholar 

  14. Yu W, Huang C, Wang Q, Huang T, Ding Y, Ma C, et al. Mef2 transcription factors promotes emt and invasiveness of hepatocellular carcinoma through tgf-β1 autoregulation circuitry. Tumor Biol. 2014;35:10943–51.

    Article  CAS  Google Scholar 

  15. Shin H-M, Seoh J-Y, Chung H-Y, Choi S-J, Hahn M-J, Kang J-S, et al. Requirement of mef2d in the induced differentiation of hl60 promyeloid cells. Mol Immunol. 1999;36:1209–14.

    Article  CAS  PubMed  Google Scholar 

  16. Prima V, Gore L, Caires A, Boomer T, Yoshinari M, Imaizumi M, et al. Cloning and functional characterization of mef2d/dazap1 and dazap1/mef2d fusion proteins created by a variant t (1; 19)(q23; p13. 3) in acute lymphoblastic leukemia. Leukemia. 2005;19:806–13.

    Article  CAS  PubMed  Google Scholar 

  17. Zhao X, Liu M, Li D. Oleanolic acid suppresses the proliferation of lung carcinoma cells by mir-122/cyclin g1/mef2d axis. Mol Cell Biochem. 2015;400:1–7.

    Article  CAS  PubMed  Google Scholar 

  18. Song L, Li D, Zhao Y, Gu Y, Zhao D, Li X, et al. Mir-218 suppressed the growth of lung carcinoma by reducing mef2d expression. Tumor Biol. 2015;1–10.

  19. Zhang H, Xue Y. Wnt pathway is involved in advanced gastric carcinoma. Hepato-gastroenterol. 2007;55:1126–30.

    Google Scholar 

  20. Cai C, Zhu X. The wnt/β-catenin pathway regulates self-renewal of cancer stem-like cells in human gastric cancer. Molecular medicine reports. 2012;5:1191–6.

    CAS  PubMed  Google Scholar 

  21. Huang J, Xiao D, Li G, Ma J, Chen P, Yuan W, et al. Epha2 promotes epithelial–mesenchymal transition through the wnt/β-catenin pathway in gastric cancer cells. Oncogene. 2014;33:2737–47.

    Article  CAS  PubMed  Google Scholar 

  22. Homminga I, Pieters R, Langerak AW, de Rooi JJ, Stubbs A, Verstegen M, et al. Integrated transcript and genome analyses reveal nkx2-1 and mef2c as potential oncogenes in t cell acute lymphoblastic leukemia. Cancer Cell. 2011;19:484–97.

    Article  CAS  PubMed  Google Scholar 

  23. Nagel S, Meyer C, Quentmeier H, Kaufmann M, Drexler H, MacLeod R. Mef2c is activated by multiple mechanisms in a subset of t-acute lymphoblastic leukemia cell lines. Leukemia. 2008;22:600–7.

    Article  CAS  PubMed  Google Scholar 

  24. Lilljebjörn H, Ågerstam H, Orsmark Pietras C, Rissler M, Ehrencrona H, Nilsson L, et al. Rna-seq identifies clinically relevant fusion genes in leukemia including a novel mef2d/csf1r fusion responsive to imatinib. Leukemia. 2014;28:977–9.

    Article  PubMed  Google Scholar 

  25. Schwieger M, Schüler A, Forster M, Engelmann A, Arnold MA, Delwel R, et al. Homing and invasiveness of mll/enl leukemic cells is regulated by mef2c. Blood. 2009;114:2476–88.

    Article  CAS  PubMed  Google Scholar 

  26. Li Y, Zhang L, Nong J, Bian S, Zhao Z, Ren Y, et al. Expression of mef2d on nasopharyngeal carcinoma tissues and its influence of prognostic. Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery. 2011;25:840–2. 847.

    CAS  PubMed  Google Scholar 

  27. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, et al. Discovery and prioritization of somatic mutations in diffuse large b-cell lymphoma (dlbcl) by whole-exome sequencing. Proc Natl Acad Sci. 2012;109:3879–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Tagawa H, Suguro M, Tsuzuki S, Matsuo K, Karnan S, Ohshima K, et al. Comparison of genome profiles for identification of distinct subgroups of diffuse large b-cell lymphoma. Blood. 2005;106:1770–7.

    Article  CAS  PubMed  Google Scholar 

  29. Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, et al. Genetic heterogeneity of diffuse large b-cell lymphoma. Proc Natl Acad Sci. 2013;110:1398–403.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Zhang M, Truscott J, Davie J. Loss of mef2d expression inhibits differentiation and contributes to oncogenesis in rhabdomyosarcoma cells. Mol Cancer. 2013;12:1–14.

    Article  CAS  Google Scholar 

  31. Shi J, Jiang X, Yu Z, He G, Ning H, Wu Z, et al. Znrf3 contributes to the growth of lung carcinoma via inhibiting wnt/β-catenin pathway and is regulated by mir-93. Tumor Biol. 2015;1–7.

  32. Ma Y, Zhu B, Liu X, Yu H, Yong L, Liu X, et al. Inhibition of oleandrin on the proliferation show and invasion of osteosarcoma cells in vitro by suppressing wnt/β-catenin signaling pathway. J Exp Clin Canc Res. 2015;34:1.

    Article  Google Scholar 

  33. Lee SC, Kim O-H, Lee SK, Kim S-J. Iwr-1 inhibits epithelial-mesenchymal transition of colorectal cancer cells through suppressing wnt/β-catenin signaling as well as survivin expression. Oncotarget. 2015;6:27146–59.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Ma Q, Yang Y, Feng D, Zheng S, Meng R, Fa P, et al. Magi3 negatively regulates wnt/β-catenin signaling and suppresses malignant phenotypes of glioma cells. Oncotarget. 2015.

Download references

Acknowledgments

The authors thank Prof. Li from the Center of Cancer Research, Boston University, USA, for the critical reading and modification of the manuscript.

Author information

Authors and Affiliations

  1. Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    Kai Xu

  2. Department of Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China

    Ying-chao Zhao

Authors
  1. Kai Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ying-chao Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ying-chao Zhao.

Ethics declarations

Conflicts of interest

None

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, K., Zhao, Yc. MEF2D/Wnt/β-catenin pathway regulates the proliferation of gastric cancer cells and is regulated by microRNA-19. Tumor Biol. 37, 9059–9069 (2016). https://doi.org/10.1007/s13277-015-4766-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-4766-3

Keywords

Search

Navigation